Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 7/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 7/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.35 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4066948 | 0.85 | ESR2 (0.41) | HSD17B10HPGDTSHRESR2LMNA | |
| SCHEMBL4065292 | 0.81 | AKR1C2 (0.39) | HSD17B10HPGDLMNAALDH1A1GAA | |
| SCHEMBL4064362 | 0.81 | ATM (0.41) | TSHRLMNAKMT2ATDP1HSP90AA1 | |
| SCHEMBL20808565 | 0.79 | ESR1 (0.47) | HSD17B10HPGDESR1ESR2LMNA | |
| SCHEMBL23919975 | 0.77 | PTGS1 (0.42) | HSD17B10HPGDESR1ESR2LMNA | |
| SCHEMBL17977154 | 0.76 | CA1 (0.45) | HSD17B10HPGDLMNAALDH1A1GAA | |
| SCHEMBL1758423 | 0.76 | ESR2 (0.48) | HSD17B10TSHRESR1ESR2PDCD1 | |
| SCHEMBL9064707 | 0.75 | TYR (0.50) | ESR1ESR2ALDH1A1GAAKMT2A | |
| SCHEMBL4063285 | 0.73 | GABRA1 (0.42) | HSD17B10HPGDTSHRESR2LMNA | |
| SCHEMBL7919375 | 0.73 | HSD17B10 (0.40) | HSD17B10HPGDTSHRESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7534547-B2 | Optically active compound and photosensitive resin composition | OSAKA GAS COMPANY LIMITED (JP) | 2009-05-19 | — | — | US | disclosed |
| EP-1375463-A1 | OPTICALLY ACTIVE COMPOUND AND PHOTOSENSITIVE RESIN COMPOSITION | Kansai Research Institute, Inc. (JP) | 2004-01-02 | — | — | EP | disclosed |
| US-20030211421-A1 | Optically active compound and photosensitive resin composition | KRI, INC. (JP) | 2003-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030211421-A1 | Optically active compound and photosensitive resin composition | ARCN1, RAD51, PAM | HSD17B10 3699/4885HPGD 146/4885TSHR 4402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.